Equities
  • Price (EUR)170.85
  • Today's Change0.00 / 0.00%
  • Shares traded5.00
  • 1 Year change-18.72%
  • Beta1.3321
Data delayed at least 15 minutes, as of Feb 18 2026 07:01 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Sartorius Stedim Biotech SA grew revenues 6.74% from 2.78bn to 2.97bn while net income improved 51.68% from 175.10m to 265.60m.
Gross margin45.33%
Net profit margin8.97%
Operating margin17.72%
Return on assets3.28%
Return on equity6.58%
Return on investment3.85%
More ▼

Cash flow in EURView more

In 2025, cash reserves at Sartorius Stedim Biotech SA fell by 252.80m. However, the company earned 692.20m from its operations for a Cash Flow Margin of 23.33%. In addition the company used 397.70m on investing activities and also paid 542.80m in financing cash flows.
Cash flow per share5.98
Price/Cash flow per share28.44
Book value per share42.04
Tangible book value per share-3.39
More ▼

Balance sheet in EURView more

Sartorius Stedim Biotech SA has a Debt to Total Capital ratio of 38.65%, a lower figure than the previous year's 70.36%.
Current ratio1.02
Quick ratio0.5313
Total debt/total equity0.6354
Total debt/total capital0.3865
More ▼

Growth rates in EUR

SmartText is unavailable
Div yield(5 year avg)0.34%
Div growth rate (5 year)0.29%
Payout ratio (TTM)25.26%
EPS growth(5 years)-5.62
EPS (TTM) vs
TTM 1 year ago
50.37
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.